Durstenfeld Matthew S, McLaughlin Megan M, Gandhi Monica, Kornak John, Beatty Alexis L, Hsue Priscilla Y
Department of Medicine, University of California San Francisco, San Francisco, USA.
Zuckerberg San Francisco General, San Francisco, USA.
J Gen Intern Med. 2025 Jun 6. doi: 10.1007/s11606-025-09642-z.
People with HIV (PWH) are at elevated risk of atherosclerotic cardiovascular disease (ASCVD), and current risk prediction tools underestimate risk among PWH. The American Heart Association developed new risk prediction equations, Predicting Risk of cardiovascular disease EVENTs (PREVENT), which have not been studied among PWH.
To compare predicted 10-year ASCVD risk using PREVENT with the pooled cohort equations (PCE) and the implications for statin recommendations among PWH.
A cross-sectional observational study using real-world, electronic health records PARTICIPANTS: All people with HIV ages 40 to 75 without cardiovascular disease at 23 primary care and HIV clinics affiliated with two health systems in San Francisco, California from 2019 to 2024 MAIN MEASURES: We compared predicted 10-year ASCVD using the PREVENT equations and the PCE. Then we considered implications of PREVENT for statin therapy using current guidelines.
Among 3357 PWH (median 57 years old; 73% male,12% female, 15% transgender/nonbinary/nondisclosed; 20% Black and 25% Latino), 91% were on antiretroviral therapy and 86% had virologic suppression. Among 2853 PWH with complete data for both calculators, the median predicted risk was 7.7% (interquartile range (IQR) 3.7, 14.0) using the PCE and 3.3% (IQR 1.9, 5.4) using PREVENT. Predicted risk was lower for 97% of individuals using PREVENT. Using a 10-year ASCVD risk threshold of 5%, only 28.6% of PWH would be strongly recommended for statins with PREVENT compared to 67.3% with PCE. The difference in predicted risk between the two equations varied across sex and race/ethnicity.
The PREVENT equations predict lower 10-year ASVCD risk for PWH compared to the PCE, which underpredicts risk for PWH. Underprediction of ASCVD risk, which -using new guidelines -would translate to 58% fewer PWH strongly recommended for statins using PREVENT compared to PCE, has the potential to increase cardiovascular disease and worsen healthcare disparities among PWH.
艾滋病病毒感染者(PWH)患动脉粥样硬化性心血管疾病(ASCVD)的风险较高,而目前的风险预测工具低估了PWH的风险。美国心脏协会制定了新的风险预测方程,即心血管疾病事件风险预测(PREVENT),但尚未在PWH中进行研究。
比较使用PREVENT与汇总队列方程(PCE)预测的10年ASCVD风险,以及对PWH他汀类药物推荐的影响。
一项使用真实世界电子健康记录的横断面观察性研究
2019年至2024年期间,加利福尼亚州旧金山两个医疗系统下属的23家初级保健和艾滋病诊所中,所有年龄在40至75岁且无心血管疾病的艾滋病病毒感染者
我们比较了使用PREVENT方程和PCE预测的10年ASCVD风险。然后,我们根据当前指南考虑了PREVENT对他汀类药物治疗的影响。
在3357名PWH中(中位年龄57岁;73%为男性,12%为女性,15%为跨性别/非二元性别/未公开;20%为黑人,25%为拉丁裔),91%接受抗逆转录病毒治疗,86%实现病毒学抑制。在2853名两个计算器都有完整数据的PWH中,使用PCE预测的中位风险为7.7%(四分位间距(IQR)3.7,14.0),使用PREVENT预测的中位风险为3.3%(IQR 1.9,5.4)。使用PREVENT时,97%的个体预测风险较低。使用10年ASCVD风险阈值5%,使用PREVENT时只有28.6%的PWH会被强烈推荐使用他汀类药物,而使用PCE时这一比例为67.3%。两个方程预测风险的差异因性别和种族/族裔而异。
与PCE相比,PREVENT方程预测的PWH 10年ASVCD风险较低,PCE低估了PWH的风险。根据新指南,ASCVD风险预测不足意味着与PCE相比,使用PREVENT被强烈推荐使用他汀类药物的PWH减少58%,这有可能增加心血管疾病风险并加剧PWH之间的医疗保健差距。